Visceral leishmaniasis associated with Wegener's disease: Utilization of lipid complex amphetericin B and liposomal amphetericin B;Leishmaniose viscerale associee a une maladie de Wegener: Utilisation de l'amphotericine B en complexes lipidiques et de l'amphotericine B liposomale

Presse Medicale

Volumn 28, Issue 18, 1999, Pages 959-961

  Zanaldi, H ^a   Rosenthal, E ^a   Marty, P ^a   Chichmanian, R M ^b   Pesce, A ^a   Cassuto, J P ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b PASTEUR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CYCLOPHOSPHAMIDE; METHOTREXATE; PREDNISONE; AMPHOTERICIN B; ANTIINFECTIVE AGENT; LIPOSOME;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DOSE KIDNEY FUNCTION RELATION; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; VISCERAL LEISHMANIASIS; WEGENER GRANULOMATOSIS; ACUTE KIDNEY FAILURE; AGED; ANEMIA; CHEMICALLY INDUCED DISORDER; FEMALE; FOLLOW UP; MALE; TREATMENT OUTCOME;

AGED; AMPHOTERICIN B; ANEMIA; ANTI-BACTERIAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, ACUTE; LEISHMANIASIS, VISCERAL; LIPOSOMES; MALE; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 0033562706     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Marty P, Lelièvre A, Quaranta JF et al. Detection by Western blot of four antigens characterizing acute clinical leishmaniasis. Trans R Soc Trop Med Hyg 1995 ; 89:690-1.
2. Izri MA, Deniau M, Briese C et al. Leishmaniasis in AIDS patients : evaluation of a fast biological method of diagnosis : the leucocytoconcentration. Bull WHO 1996 ; 74:91-4.
3. Sundar S, Murray KW. Cure of antimony-unresponsive. Indian visceral leishmaniosis with amphotericin B lipid complex. J Infect Dis 1996 ; 173:762-5.
4. Gradoni L, Bryceson A, Desjeux P. Treatment of mediterranean visceral leishmaniasis. Bull WHO 1995 ; 73:191-7.
5. Jambou D, Belloi A Marty P et al. La leishmaniose dans les Alpes Maritimes de 1975 à 1984. Bul Soc Path Exp 1986 ; 79:620-8.
6. Kubar J, Marty P, Lelièvre A et al. Visceral leishmaniosis in HIV positive patients : primary infection, reactivation and latent infection. AIDS 1998 ; 12:2147-53.
7. Rosenthal E, Marty P, Poizot-Martin I et al. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 1995 ; 89:195-62.
8. Kubar J, Quaranta JP, Marty P, Lelièvre A, Lefichoux Y, Aufeuvre JP. Transmission of Leishmania infantum by blood donnors. Nature Medicine 1997 ; 3:368.
9. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B : recent progress and future directions. Clin Infect Dis 1996 ; 22(suppl 2):s133-44.
10. Heinemann V, Kiahny B, Debus A, Wachholz K, Jehn U. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid - based formulations. Bone Marrow Transplant 1994 ; 14(suppl 5):s8-9.
11. Walsh TJ, Hiemenz JW, Siebel NL et al. Amphotericin B lipid complex for invasive fungal infections : analysis of safety and efficacy in 556 cases. Clin Infect Dis 1994 ; 26:1383-96.
12. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloïdal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995 ; 21:1145-53.
13. Hospenthal DR, Byrd JC, Weiss RB. Successful treatment of invasive aspergillosis complicating prolonged treatment related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex. Med Ped Oncol 1995 ; 25:119-22.
14. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients : a single experience of 11 episods in 116 patients. Brit J Haematol 1994 ; 86:754-60.
15. Rosenthal E. Clinical manifestations of visceral leishmaniasis in HIV-infected patients. III Consultative meetings on leishmania/HIV co-infections. WHO-UNAIDS, Menorca, Spain. September 26-29 1998.